Search

KR-20260062399-A - composition for improving and treating obesity comprising of alpinumisoflavone or its derivatives as active ingredients

KR20260062399AKR 20260062399 AKR20260062399 AKR 20260062399AKR-20260062399-A

Abstract

The present invention relates to a composition for improving and treating obesity comprising alpinum isoflavone or a derivative thereof as an active ingredient. The composition of the present invention inhibits the expression of TM4SF19 induced by 25-hydroxycholesterol in macrophages and has a weight-loss effect in individuals, so it can be used as a useful composition for the prevention, improvement, or treatment of obesity.

Inventors

  • 김관회
  • 이동호
  • 손용해
  • 박동하
  • 김재성

Assignees

  • 부산대학교 산학협력단
  • 고려대학교 산학협력단

Dates

Publication Date
20260507
Application Date
20241029

Claims (6)

  1. A food composition for improving and preventing obesity comprising alpinum isoflavone or a derivative thereof as an active ingredient.
  2. In paragraph 1, A food composition for improving and preventing obesity, wherein the above-mentioned alpinum isoflavone derivative is one or more compounds selected from the group consisting of 4'-O-methylalpinum isoflavone, O,O-dimethylalpinum isoflavone, 5-O-acetyl-4'-methoxyalpinum isoflavone, 4'-O-acetylalpinum isoflavone, erythrinine A, parvisoflavone B, scandenolone, and cudraisoflavone H.
  3. In paragraph 1, A food composition for improving and preventing obesity, wherein the above-mentioned alpinum isoflavone or derivative thereof inhibits the expression of TM4SF19 induced by 25-hydroxycholesterol in macrophages.
  4. A pharmaceutical composition for the treatment and prevention of obesity comprising alpinum isoflavone or a derivative thereof as an active ingredient.
  5. In paragraph 4, A pharmaceutical composition for the treatment and prevention of obesity, wherein the alpinaum isoflavone derivative is one or more compounds selected from the group consisting of 4'-O-methylalpinum isoflavone, O,O-dimethylalpinum isoflavone, 5-O-acetyl-4'-methoxyalpinum isoflavone, 4'-O-acetylalpinum isoflavone, erythrinine A, parvisoflavone B, scandenolone, and cudraisoflavone H.
  6. In paragraph 4, A pharmaceutical composition for the treatment and prevention of obesity, wherein the above-mentioned alpinum isoflavone or derivative thereof inhibits the expression of TM4SF19 induced by 25-hydroxycholesterol in macrophages.

Description

Composition for improving and treating obesity comprising of alpinum isoflavone or its derivatives as active ingredients The present invention relates to a composition for improving and treating obesity comprising alpinum isoflavone or a derivative thereof as an active ingredient. Obesity refers to a condition in which fat is excessively accumulated in the body and is recognized as one of the most serious health problems in modern society. According to the World Health Organization (WHO), the global obese population is rapidly increasing; as of 2022, approximately 2.5 billion adults aged 18 and older worldwide were overweight, with 890 million of them being obese (World Health Organization, "Obesity and overweight" Fact sheet, March 1, 2021). These statistics indicate that 43% of adults aged 18 and older (43% of men and 44% of women) are overweight, and obesity acts as a risk factor for various chronic diseases beyond the mere issue of weight gain. Obesity can be caused by various factors, but it is primarily resulting from an imbalance between energy intake and expenditure. Changes in modern dietary habits, reduced physical activity, and increased stress are identified as major causes of obesity. Additionally, genetic factors, hormonal imbalances, and drug side effects are also known to induce obesity. Obesity caused by these factors can lead to various health problems and is known to increase the risk of developing conditions such as type 2 diabetes, hypertension, cardiovascular disease, stroke, and certain types of cancer (breast cancer, colorectal cancer, etc.). Furthermore, obesity can cause not only physical issues such as arthritis, sleep apnea, and infertility, but also mental problems like depression and low self-esteem, negatively impacting the overall quality of life. Various methods are being attempted for the treatment and management of obesity. The most basic methods are dietary and exercise therapy, which form the foundation of obesity management. While reducing calorie intake and increasing physical activity is the core of obesity management, many people struggle to consistently practice this. Pharmacological treatment for obesity is considered when dietary and exercise therapy alone are ineffective. Currently available obesity treatments include appetite suppressants and fat absorption inhibitors, but their long-term use is limited due to the risk of side effects. For example, fat absorption inhibitors such as Orlistat have been reported to cause side effects such as steatorrhea and abdominal bloating, while appetite suppressants like Phentermine may cause side effects such as insomnia, headaches, and increased blood pressure. Additionally, surgical treatment methods such as gastric banding and gastric bypass surgery can be considered; however, these are limited to patients with severe obesity, and a cautious approach is required due to the risks associated with surgery and the possibility of complications. As such, obesity is emerging as a major health issue in modern society, and various approaches are being attempted to address it. However, existing treatments still show limitations in terms of efficacy, safety, and sustainability, making the development of new, more effective, and safe methods for improving and treating obesity an urgent necessity. Against this backdrop, the demand for new obesity treatment methods that are effective yet have few side effects is continuously increasing, and in particular, interest in compositions for improving and treating obesity utilizing naturally derived ingredients is growing. Naturally derived ingredients are attracting attention as an alternative for obesity management because they generally have fewer side effects and can be used for a long period compared to synthetic drugs. Figure 1 is a schematic diagram showing that when 4'-O-methylalpinum isoflavones are administered to mice fed a high-fat diet, the rate of body weight gain decreases and the expression of the obesity-related gene TM4SF19 is suppressed when macrophages are exposed to 4'-O-methylalpinum isoflavones. Figure 2 confirms that 4'-O-methylalpinum isoflavone (mAI) inhibits TM4SF19 expression induced by 25-hydroxycholesterol (25OHChchol) in a concentration-dependent manner. Figure 3 shows the change in body weight and the decrease in the rate of weight gain in the group of mice administered 4'-O-methylalpinum isoflavone (mAI) after a high-fat diet (HFD). The definitions of terms used in the present invention are as follows: "Obesity" is a phenomenon in which excess energy is accumulated as body fat due to an imbalance between energy consumed through food and energy consumed through physical activity, and may be obesity caused by food intake, obesity due to nervous gastritis, obesity due to excessive gluten, obesity due to venous circulation disorder, or metabolic obesity. In the present invention, metabolic obesity may be the cause of diabetes, hyperlipidemia, heart disease, stroke,